RxDoctor Payments Data

Maxine Gustafson, PA

Physician Assistant · Edina, MNNPI 1083127203

Payments from drug & device makers

$2,734in general payments, 2019–2025

Across 78 payments — averaging $35.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$952
  • Coloplast$296
  • Boston Scientific$288
  • Medical Device Business Services, Inc.$272
  • Dendreon Pharmaceuticals LLC$215
  • Ferring Pharmaceuticals Inc.$109
  • plus $600 from 15 others

What the payments were for

  • Food & beverage$2,59795%
  • Education$1375%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,734 in reported general payments places this provider in the 95th percentile of 3,121 physician assistant providers in Minnesota.

See all physician assistant providers in Minnesota

Medicare billing

Part B allowed, 2024
$38,446
Medicare patients
262
Services billed
1,078

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron129$97,376
MyrbetriqMirabegron120$78,588
Estradiol85$4,359
Trospium Chloride ErTrospium Chloride18$3,041
Trimethoprim31$2,026
Fosfomycin Tromethamine11$1,859
Tamsulosin Hcl148$1,754
Cephalexin58$942
Oxybutynin Chloride ErOxybutynin Chloride41$658
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst30$542
Finasteride26$326
Ciprofloxacin Hcl58$218
Alfuzosin Hcl ErAlfuzosin Hcl15$196
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim30$100
Oxycodone Hcl38$80

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$29$78,588120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,121 physician assistant providers in Minnesota.

Other physician assistant in Edina

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →